Asthma is a common chronic inflammatory disease of the airways.
哮喘是一种常见的慢性气道炎症性疾病。
People with
asthma experience symptoms like wheezing, shortness of breath, and coughing.
哮喘患者会出现喘息、呼吸短促和咳嗽等症状。
The triggers for
asthma can vary from person to person and may include allergens, exercise, or cold air.
哮喘的诱因因人而异，可能包括过敏原、运动或冷空气。
Inhalers containing bronchodilators and corticosteroids are often prescribed to manage
asthma symptoms.
含有支气管扩张剂和皮质类固醇的吸入器常被用来控制哮喘症状。
It's important for those diagnosed with
asthma to have an action plan in place for
asthma attacks.
对于被诊断为哮喘的人而言，制定应对哮喘发作的行动计划至关重要。
Regular exercise, when done under a doctor's guidance, can actually improve
asthma control over time.
在医生的指导下进行规律锻炼，实际上可以随时间改善对哮喘的控制。
Childhood
asthma, if not properly managed, can lead to long-term respiratory problems in adulthood.
儿童哮喘如果管理不当，可能导致成年后的长期呼吸道问题。
Environmental factors such as pollution and tobacco smoke can exacerbate
asthma symptoms.
环境因素，如污染和烟草烟雾，会加剧哮喘症状。
Asthma is not curable, but with proper treatment and management, people with
asthma can lead full, active lives.
哮喘虽无法治愈，但通过适当的治疗和管理，哮喘患者可以过上充实、活跃的生活。
During an
asthma flare-up, the airways become inflamed, narrow, and produce extra mucus, making it hard to breathe.
哮喘发作时，气道会发炎、变窄并产生额外的粘液，导致呼吸困难。
In the company's most recent moves, Lin noted that AstraZeneca established a new production and supply base for an asthma inhaler in Qingdao, East China's Shandong province, in March, with an initial investment of $450 million, adding that in August, it invested an additional $250 million to further expand its capacity for canning production and aerosol inhalation packaging production.
在该公司最近的举措中，林指出，阿斯利康于3月在中国东部山东省青岛市建立了一个新的哮喘吸入器生产和供应基地，初始投资4.5亿美元，并补充说，8月，该公司额外投资2.5亿美元，以进一步扩大其罐装生产和气雾剂吸入包装生产的能力。
A paper by Chinese researchers published in The Lancet in 2019 showed that China had 45.7 million asthma patients aged 20 and older and 15 million asthma sufferers aged below 20.
中国研究人员2019年发表在《柳叶刀》上的一篇论文显示，中国有4570万20岁及以上的哮喘患者，1500万20岁以下的哮喘患者。
GSK currently has two potential COPD and two potential asthma trials with Chinese patients, Yu said.
郁说，葛兰素史克目前有两项针对中国患者的潜在COPD和两项潜在哮喘试验。
For instance, the company has partnered with the Guangzhou Institute of Respiratory Health since 2017 to establish a collaborative network and database for managing asthma patients in China.
例如，该公司自2017年起与广州呼吸健康研究所合作，建立了一个用于管理中国哮喘患者的协作网络和数据库。
The collaboration entered into the second phase last year to recruit 110 hospitals to join and register clinical data for approximately 18,000 asthma sufferers, aiming to ultimately improve the level of disease control of such patients in the country.
该合作于去年进入第二阶段，招募了110家医院加入并登记了约18000名哮喘患者的临床数据，旨在最终提高该国此类患者的疾病控制水平。
Shen Huahao, vice-chairman of the respiratory branch of the Chinese Medical Association, said that more efforts should be made to popularize standard medical treatment for asthma patients at a grassroots level.
中华医学会呼吸内科分会副会长沈华浩表示，应加大力度在基层普及哮喘患者的标准医疗。
The control rate of asthma in urban regions is only 28.5 percent, and the rate is lower in rural areas due to the huge gap in medical resources, said Shen, who is also director of the department of respiratory and critical care medicine at the Second Affiliated Hospital with Zhejiang University School of Medicine.
同时也是浙江大学医学院附属第二医院呼吸与危重症医学科主任的沈说，城市地区的哮喘控制率仅为28.5%，而农村地区由于医疗资源的巨大缺口，哮喘控制率较低。
Global pharmaceutical company AstraZeneca will introduce a batch of innovative drugs into China by 2025 for the treatment of respiratory diseases, such as severe asthma, chronic cough and chronic obstructive pulmonary disease, according to Lin Xiao, vice-president of the company's China branch.
全球制药公司阿斯利康中国分公司副总裁林晓表示，到2025年，该公司将向中国引进一批创新药物，用于治疗严重哮喘、慢性咳嗽和慢性阻塞性肺病等呼吸道疾病。
In recent years, Chiesi's portfolio of products has expanded from mainly neonatology to include respiratory solutions for all age groups, especially those who have respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease.
近年来，Chiesi的产品组合已从主要的新生儿科扩展到包括适用于所有年龄组的呼吸系统解决方案，尤其是那些患有哮喘和慢性阻塞性肺病等呼吸系统疾病的人。
According to recent pulmonary health studies among the Chinese population, 4.2 percent of adults aged above 20 in the country suffer from asthma.
根据最近在中国人群中进行的肺部健康研究，中国20岁以上的成年人中有4.2%患有哮喘。